Costa Carlos 4
4 · Foghorn Therapeutics Inc. · Filed Sep 18, 2024
Insider Transaction Report
Form 4
Costa Carlos
Chief People Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-16$3.72/sh+400$1,488→ 400 total - Sale
Common Stock
2024-09-16$10.00/sh−400$4,000→ 0 total - Exercise/Conversion
Common Stock
2024-09-17$3.72/sh+10,272$38,212→ 10,272 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-16−400→ 98,248 totalExercise: $3.72Exp: 2029-02-12→ Common Stock (400 underlying) - Sale
Common Stock
2024-09-17$10.04/sh−10,272$103,131→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-17−10,272→ 87,976 totalExercise: $3.72Exp: 2029-02-12→ Common Stock (10,272 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.18 per share.
- [F3]The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested.